It's here! SWOG’s fall group meeting takes place next week, in Chicago and online (for most events). A look at our new meeting app shows a packed agenda, with more than 80 sessions.

You can install the app to your smart phone, or you can use the online version in a browser. It’s convenient for building an itinerary for your week, for connecting with colleagues, and for claiming continuing medical education (CME) credit.

Although we still have our traditional agenda book in digital form, online and in the meeting app, we won’t offer you a 100-page paperback version to lug around once you arrive at the hotel. So, plan ahead and check out the meeting app before you go.

Here are a few previews of events you’ll find on the app calendar:

  • The DEI Town Hall (Thursday, 2 – 3 pm) will be a chance to ask questions about our diversity, equity, and inclusion initiatives – why they matter, how we’ll show progress, and more. We’ll also hear from Dr. Christopher Cross, director of health equity strategies at ASCO’s Center for Equity, Diversity, and Inclusion.
  • At our community advocate networking event (Thursday, 5 – 6:30 pm), you can meet and interact with advocates Joël Pointon, representing the LGBTQ+ community, and Lauren Fryzel, representing the AYA community.
  • The NCORP Research Base Clinical Trials Workshop (Wednesday, 11:30 am – 3:30 pm) will provide information on conducting clinical trials run by SWOG’s five cancer control and prevention committees.
  • The SWOG Clinical Trials Partnerships Update Forum (Wednesday, 11:30 am – 12:30 pm) will answer your questions about what your site can expect as the first trials developed in CTP’s Preferred Partnerships Program approach activation.
  • Our SWOG Latin America Initiative Symposium (Thursday, 11 am – 1 pm) will highlight tobacco and tobacco-related cancers in Latin America and among Hispanic patients in the U.S.
  • The Open Forum sponsored by our oncology research professionals committee (Thursday, 12:30 – 2 pm) may take the prize for the greatest number of educational topics covered in a single group meeting event. If you find it difficult to take it all in (10 round tables in four sessions doesn’t divide evenly), remember that we’ll hold another group meeting come April.
  • Thursday’s translational medicine plenary (3:30 – 5 pm) will feature a mini-symposium on CIMACs – the NCI’s Cancer Immune Monitoring and Analysis Centers.
  • Our general plenary session (Friday, 12 – 2 pm) explores the impact a generation of Hope Foundation support has had on SWOG and its work. Merriam-Webster’s defines “plenary” as fully attended or constituted by all entitled to be present, so I assume all members will attend.

By my count, we have 22 sessions offering CME credits this fall. Our new meeting app offers a system for claiming these credits that’s more user friendly than what we’ve offered with past group meetings. We also have a number of sessions that can earn members continuing education credits from the Society of Clinical Research Associates (SOCRA).

So, download the app, pack your bag, and see you in Chicago, very soon

As usual with group meeting week, we’ll skip next Friday’s Front Line. We’ll check in again October 20th.



Trial of the Week

1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-Map Sub-Study)

Sotorasib won FDA approval for use in non-small cell lung cancer featuring KRAS G12C mutations. S1900E asks how the efficacy of sotorasib is affected when certain co-mutations are also present. The trial provides sotorasib at no cost to patients.

The study activated in April of 2021, and to date has accrued 102 of a planned 116 patients, at 70 sites, out of more than 800 sites that have opened the trial.  

The University of Rochester and the UPMC Hillman Cancer Center are the leading accruers to the study (and leading accruers to Lung-MAP overall in recent years).

The study chairs are Sukhmani Padda, MD, of Cedars-Sinai Medical Center, and David E. Gerber, MD, of UT Southwestern Medical Center.

You can learn more on the SWOG S1900E page or the CTSU S1900E page. 

When you present S1900E to a patient, provide them a copy of the patient-friendly summary of the S1900E sub-study (and a copy of the patient-friendly summary of the Lung-MAP trial).

Other Recent Stories

Lung-MAP: A lung cancer precision medicine trial
Dec 1, 2023
Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research